No Data
Teva Pharmaceutical Industries Subsidiary And Medincell Says European Medicines Agency Has Accepted The Marketing Authorization Application For Olanzapine Long-Acting Injectable (TEV-'749) For The Treatment Of Schizophrenia In Adults
Teva Pharmaceuticals International GmbH Wins EU Approval For Denosumab Biosimilars PONLIMSI And DEGEVMA
Teva Pharmaceutical's Unit Enters License Agreement With Prestige Biopharma To Commercialize Tuznue Across Majority Of European Markets
Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea (Aflibercept) in Major Parts of Europe and in Israel
Samsung Bioepis and Teva Enter Into a Strategic Partnership for Commercialization of EPYSQLI (Eculizumab-aagh) in the United States
National Bank on Andlauer Health -- Maintains Outperform,$58.75 Target